China's Pharmaceutical Innovation Capacity Continues to Rise as Companies Secure Over RMB 100 Million in Funding

　　【Pharmaceutical Network Industry Dynamics】In 2025, global biopharmaceutical financing remained active. For instance, in March, over 140 financing deals were completed globally, totaling more than $4.5 billion. In December, numerous companies completed over 130 financing deals with a total value exceeding $3.4 billion. Among them, Chinese companies also performed remarkably, with many raising over 100 million yuan, covering areas such as innovative drug R&D, cell and gene therapy services, and intelligent surgery.RobotIn multiple fields such as .
 

Recently, BRC BIOTECHNOLOGY, which focuses on biopharmaceutical safety testing services, announced that it has successfully completed an A-round financing of over 100 million RMB. The funds from this round will mainly be used to expand global presence, accelerate the development of a GMP-compliant biosafety testing platform, and continuously improve the high-quality biosafety industry layout. Notably, as of this round, BRC BIOTECHNOLOGY has completed cumulative financing of over 300 million RMB.
 

December 26, HemaCell, a cellular biopharmaceutical company, has completed a B1 round of financing exceeding 100 million yuan. HemaCell is committed to achieving blood cell regeneration through stem cell technology for application in cell therapy and new drug development. The funds from this round will be used to advance the research on stem cell-directed regeneration of blood cells for therapeutic purposes and drug development.
 

On December 27, Shenzhen Weide Precision Medical Technology Co., Ltd. announced the completion of a B-round financing exceeding 1.2 billion yuan. In the future, the company will accelerate its market layout, aiming to achieve an annual surgery volume of over 6,000 by 2026; promote global expansion through innovative channel products and international certifications; and continue to deepen clinical collaborations, transforming top experts' surgical experiences into standardized intelligent solutions to provide more patients with precise and safe interventional surgeries.
 

On December 16, AI pharmaceutical R&D company PHIL RIVERS TECHNOLOGY Co., Ltd completed an approximately 100-million-yuan A1 round of financing, led by Guoke Investment, with participation from Zeyuan Fund and RuiZhi Medicine. The funds will be used to advance digital life technology R&D and the discovery of new tumor targets.
 

On December 9, Suzhou Sine Biomedicine Co., Ltd. announced the completion of a Series B financing round exceeding 110 million US dollars. The success of this Series B financing will further enhance Sine Biomedicine's investment in research and development, accelerating the clinical translation and industrialization process of small nucleic acid drugs.
 

　　……
 

From an overall perspective, China's pharmaceutical financing in 2025 is showing a trend of reduced volume but increased amount, with capital concentration in leading players. At the same time, substantial funds are being directed toward assets with clinical value and global competitiveness. Industry insiders believe this signifies that China’s pharmaceutical industry has entered a new phase of "core innovation" and "efficiency innovation." In the future, this financing will be transformed into actual momentum for R&D investment, production capacity upgrades, and market expansion, driving China’s pharmaceutical industry to accelerate high-quality development.
 

However, it is worth noting that the key to enterprises gaining more capital favor and ultimately succeeding in the industrial transformation will also depend on whether they can produce new globally competitive achievements at a lower cost and with higher efficiency in the future.
 

　　Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.